We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+11.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.92B
AUM Growth
-$2.46M
Cap. Flow
-$121M
Cap. Flow %
-3.08%
Top 10 Hldgs %
77.48%
Holding
132
New
21
Increased
29
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$103M
2
CGEM icon
Cullinan Oncology
CGEM
+$22.5M
3
RNAM
Avidity Biosciences
RNAM
+$18.8M
4
VERA icon
Vera Therapeutics
VERA
+$16.3M
5
JBIO
Jade Biosciences
JBIO
+$15.3M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$232M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$29.5M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.8M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$16.1M
5
ONC
BeOne Medicines Ltd
ONC
+$15.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 56.02%
2 Healthcare 41.9%
3 Technology 0.98%
4 Financials 0.15%
5 Consumer Staples 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAVA icon
1
CAVA Group
CAVA
$8.43B
$2.18B 55.59%
23,507,990
-3,000,000
-11% -$232M
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$294M 7.5%
175,099,384
+57,546,100
+49% +$103M
SRRK icon
3
Scholar Rock
SRRK
$6.46B
$93.8M 2.39%
11,259,438
– –
KYMR icon
4
Kymera Therapeutics
KYMR
$9.51B
$89.7M 2.29%
3,005,610
-21,525
-0.7% -$745K
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$86.1M 2.19%
2,525,998
+312,810
+14% +$9.27M
ARWR icon
6
Arrowhead Research
ARWR
$12.1B
$82.9M 2.11%
3,189,389
+152,721
+5% +$3.75M
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
$56.3M 1.43%
1,467,080
+151,798
+12% +$6.87M
DYN icon
8
Dyne Therapeutics
DYN
$4.85B
$53.5M 1.36%
1,516,960
-1,000
-0.1% -$29.1K
SLN
9
Silence Therapeutics
SLN
$660M
$52.8M 1.35%
2,779,619
– –
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$49.5M 1.26%
1,313,026
-102,322
-7% -$4.31M
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$8.96B
$47.7M 1.22%
1,066,064
-324,413
-23% -$15M
MRUS
12
DELISTED
Merus
MRUS
$45M 1.15%
760,355
+305,274
+67% +$14.8M
ONC
13
BeOne Medicines Ltd
ONC
$40.3B
$43.3M 1.1%
303,369
-101,413
-25% -$15.6M
RVMD icon
14
Revolution Medicines
RVMD
$43.3B
$39.4M 1.01%
1,015,776
-302,873
-23% -$11.3M
KURA icon
15
Kura Oncology
KURA
$896M
$37.5M 0.96%
1,819,884
-100,000
-5% -$2.06M
VERA icon
16
Vera Therapeutics
VERA
$2.08B
$33.1M 0.84%
915,974
+409,955
+81% +$16.3M
NMRA icon
17
Neumora Therapeutics
NMRA
$321M
$27.8M 0.71%
2,824,052
-100,000
-3% -$1.03M
CYTK icon
18
Cytokinetics
CYTK
$10.2B
$26.8M 0.68%
494,421
-12,163
-2% -$734K
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$26.8M 0.68%
+655,555
New +$18.8M
ARWR icon
20
CALL
Arrowhead Research
ARWR
$12.1B
$26M 0.66%
1,000,000
+400,000
+67% +$9.83M
IGMS
21
DELISTED
IGM Biosciences
IGMS
$22.9M 0.58%
3,330,422
+250,000
+8% +$2.14M
WVE icon
22
Wave Life Sciences
WVE
$1.02B
$22.8M 0.58%
4,566,251
+514,851
+13% +$2.94M
ERAS icon
23
Erasca
ERAS
$6.25B
$22.7M 0.58%
9,630,810
+4,909,616
+104% +$10.6M
TNGX icon
24
Tango Therapeutics
TNGX
$4.32B
$21.6M 0.55%
2,519,841
+325,000
+15% +$2.51M
PRTA icon
25
Prothena Corp
PRTA
$466M
$20.7M 0.53%
1,001,360
– –
1
2 3 4 5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q2 2024 Portfolio in Review

As of Q2 2024, Artal Group held 132 positions worth $3.92B, down 0.06% from $3.93B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Artal Group withdrew a net $121M in Q2 2024, closing 20 positions and reducing 29 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $29.5M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 56% of assets, up from 48% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Artal Group opened a new position in Cullinan Oncology worth $18.5M.

  • Artal Group's largest Q2 2024 buy was Cullinan Oncology: 1,057,949 shares worth $18.5M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2024, an estimated $103M increase.
  • Artal Group's biggest Q2 2024 reduction was CAVA Group, cutting an estimated $232M.
  • Artal Group fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $29.5M.
  • Artal Group's ten largest holdings make up 77% of its $3.92B portfolio in Q2 2024.
  • Artal Group opened 21 new positions and closed 20 in Q2 2024.
  • Artal Group's portfolio value fell 0.06% quarter-over-quarter to $3.92B.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.